Showing 1-9 of 9 "Lymphoma"

Status: Open Not Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Erick Villarreal-Williams

Phone: 713.441.9775

This is an open-label, multicenter, phase 2 study to evaluate the efficacy and safety of oral MLN9708 in adult patients with follicular lymphoma (FL) that is relapsed and/or refractory to prior treatment. ... Read more >

Status: Open Not Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Bhavin Shah

Phone: 832.279.5111

This is a Phase I clinical trial for patients with either non-Hodgkins lymphoma (NHL) or renal cell carcinoma (RCC) who have been previously treated. The cancer either did not respond to the last treatment or the cancer has come back. This study ... Read more >

Status: Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Bhavin Shah

Phone: 832.279.5111

This is an open-label, dose-escalation/dose-expansion study of INCB057643 in subjects with advanced malignancies. Part 1 will determine the maximum tolerated dose of INCB057643 and/or a tolerated dose that demonstrates sufficient pharmacologic a ... Read more >

Status: Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Karen Woodard

Phone: 713.441.4332

Open-label, dose-escalation study in subjects with previously treated B-cell malignancies to find maximum tolerated dose (MTD) or pharmacologic active dose of a PI3Kδ inhibitor, INCB050465, as monotherapy and in combination with: itacitinib (INC ... Read more >

Status: Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Karen Woodard

Phone: 713.441.4332

The purpose of this study is to evaluate the safety/tolerability and efficacy of itacitinib in combination with ibrutinib in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) ... Read more >

Status: Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Bhavin Shah

Phone: 832.279.5111

This study is an open-label, multicenter, phase 1, dose escalation study of TAK-659 in adult patients with advanced solid tumor and lymphoma malignancies. This study will be the first to administer TAK-659 to humans. The patient population durin ... Read more >

Status: Active

Investigator: Swaminathan Iyer

Study Coordinator: Bhavin Shah

Phone: 832.279.5111

This open-label, multicenter, global study is designed to determine the recommended phase 2 dose, safety, efficacy, and pharmacokinetics/pharmacodynamics of durvalumab in subjects with certain lymphoma subtypes or CLL. Globally, 253 subjects may ... Read more >

Status: Open Not Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Bhavin Shah

Phone: 832.279.5111

This multi-center, open-label, dose-finding study will evaluate the safety and pharmacokinetics of GDC-0199 (ABT-199) administered in combination with obinutuzumab to patients with relapsed/refractory or previously untreated chronic lymphocytic ... Read more >

Status: Enrolling

Investigator: Swaminathan Iyer

Study Coordinator: Bhavin Shah

Phone: 832.279.5111

This is a Phase 2, open-label, multicenter trial designed to evaluate the efficacy and safety of CUDC-907 monotherapy and R-907 (rituximab in combination with CUDC-907) in subjects 18 years and older with Relapsed/Refractory (RR) MYC-altered Dif ... Read more >